Bristol Myers Squibb Company presented data on 11 June showing that its erythroid maturation drug Reblozyl can increase hemoglobin in 77% of patients with non-transfusion-dependent (NTD) beta thalassemia compared to zero on placebo, perhaps positioning the product to add a third indication to its label.
Although the Phase II BEYOND study readout is unlikely to serve as pivotal data, Noah Berkowitz, BMS’s senior vice president...
Welcome to Scrip
Create an account to read this article
Already a subscriber?